Lexeo Therapeutics (LXEO) stock

Gene therapy , market cap $251M

Gene therapy for cardiovascular diseases

Market cap $251M

$3.06

-2.55%

After-hours $3.06 0.00%

As of 6:23 PM ET after-hours, delayed 15+ min · Live for Pro members

Quality Score

-13

Poor

In its industry

#289of 291

Biotech

Checks firing

0of 14

Trending down

From 52-week high

-72.2%

Below the 200-day

LXEO's Quality Score fell 1 point on Mon, Nov 2, to -13.

Follow LXEO's trial news. Pro members can get an alert when Lexeo Therapeutics files news, and see its trials, share raises, and its CEO's filings.

Get an alert when LXEO files news on its trialsSee it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

NextQ4 2026“…patients dosed in the low and high dose cohorts Data update for high-dose participants expected in Q4 2026…”Trial data · SEC filing · Aug 12

Cash$234M, about 10 quarters (2.5 years) at the last year's spendingOn Jun 30 · the company says “into 2028”

Why is LXEO down?

Down 25% in 3 months while the S&P 500 was flat.

It filed a prospectus for an offering of shares on Oct 17, 2025.

Sources: Price history, Oct 30, 2026; Prospectus supplement, Oct 17, 2025

−3Long-term trend below a falling 200-day average, down over one year, down over two years

The other side, how the business stands, and the timeline, for Pro members.

Get an alert when LXEO's Quality Score turns up →

Key facts on LXEO

Key facts on LXEO
Holding it back	96.5% more shares than a year ago from Massive's market data
Latest filing	S-3, Oct 29 Registered shares for a later sale (S-3)

1 more reason behind LXEO's -13, free with an account →4 more reasons behind LXEO's -13, for Pro members.

LXEO in the news

ReportExpected to report Wednesday, before the open. Every 3 months, a company tells everyone how much it sold and earned. It rose after 3 of its last 4 reports, +3.5% on average. Past reports ›

Tested. Our top-⁠scored stocks returned 2.2x the average stock over the next month. How we tested it

Cash$234M, about 10 quarters (2.5 years) at the last year's spendingOn Jun 30 · the company says “into 2028”

LXEO catalysts

Coming up

After its last 4 reports it closed +3.5% on average, higher 3 of 4 times.

3 more coming up and 2 past catalysts since 2026, with sizes and sources, for Pro members.Get in free →

What's next for LXEO, and how long its cash lasts

Next step the company has named

Q4 2026“…measures across patients dosed in the low and high dose cohorts Data update for high-dose participants expected in Q4 2026; regulatory engagement expected in 2026 PKP2 Arrhythmogenic…”Trial data · SEC filing · Aug 12

What it means: the first look at a trial’s main results, as the company reports them.

A trial underway: Gene Therapy for ACM Due to a PKP2 Pathogenic VariantPhase 1/2 · Active · 10 people · main data estimated Dec 2026 · NCT06109181

3 more trials, 3 more milestones and 38 filings, for Pro members.

Cash runway Jun 30 balance sheet

About 10 quarters

$234M in cash and investments (as the company counts them), at its spending over the last year

What it means: how long the cash would last at the same pace, before any new money. The company's estimate is “into 2028” (8-K, Sep 22).

For Pro members: the cash used each quarter, and the math.

Dilution on the horizon

Shelf registration (S-3, filed Oct 29, 2026)
At-the-market share sales program (S-3, filed Oct 29, 2026)

For Pro members: 3 raises and their amounts, and the share count against a year ago.

Insiders

CFO Louis Edward Tamayo sold 4,117 shares on Aug 18. 11 more insider trades this year.

From Form 4: open-market buys and sales only.

Get an alert when Richard Townsend buys or sells

For Pro members: every trade, and Richard Townsend’s 20 filings and quotes.

Get an alert when LXEO files news on its trialsSee it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

In 20 daysFDA decisionIn 20 days · FDA decisionCAPRCapricor TherapeuticsDeramiocelCAPRCapricor Therapeutics · $385MDeramiocelFDA decision due (PDUFA)
In 20 daysFDA decisionIn 20 days · FDA decisionSVRASavaraMolgramostimSVRASavara · $1.0BMolgramostimFDA decision due (PDUFA)
In 50 daysFDA decisionIn 50 days · FDA decisionMLYSMineralys TherapeuticsLorundrostatMLYSMineralys Therapeutics · $1.9BLorundrostatFDA decision due (PDUFA)

11 more FDA dates and 102 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 143 dates, ranked →

Here is what Pro members see.

The same page for Pro members, on AMD
Its Quality Score and rank, the line that drives it, and the live price.
The full chart
A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.
Every line of the score
Price action, the company, and signals, each with its points, on LXEO and every other stock.
FDA dates, counted down
Each date in the company's words, its cash against the date, and an optional alert before it.
CEOs buying their own stock
Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.
Congress trades
A member's trades, newest first, each with its amount. Sort and filter the whole list.
14 chart checks, read for you
The ones firing on the stock, each in plain words, its rule a tap away.
Earnings, week by week
Who reports each day, and how each stock took its last four reports.
The market map
Every stock a box, colored by its Quality Score.
Themes, ranked live
Each theme's stocks ranked by Quality Score, live. Here, AI chips.
The top 10, every day
The ten highest Quality Scores at each close, kept day by day, week by week.
Optional alerts, your way
Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.
Your watchlist, scored
Your stocks by Quality Score, today's move, or name.
On your phone and your laptop
The same account and watchlist on both, each laid out for its screen.

Prices refresh every 2.5 seconds during market hours.
Optional alerts by push, email, or the bell.
Add it to your Home Screen and it opens like an app.

Nothing is firing on LXEO right now

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Volume1 of 3 shown

VOL VDU U/D VOL

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

Buying1 of 3 shown

OBV+CLOSE HI SPRING

The other 10 checks on LXEO, and all 14 on every stock.Get in free →

LXEO RSI today: 46.1, below its 50-day and 200-day averages

Not scored

Not in the Quality Score: over 20 years of tests, 2006 to 2026, they added no edge.

RSI 1446.1
Above 30, below 50.
MACD (12, 26, 9)Above signal
Crossed above its signal line 9 sessions ago.
50-day average$3.72
The price is 17.7% below it.
200-day average$5.19
The price is 41.0% below it.
50/200 crossDeath cross
The 50-day crossed below the 200-day on Mar 26.
ADX 1426.4
25 or more, with +DI below -DI.
Support$2.98
Swing low from Sep 29, 2.6% below the price.
Resistance$3.69
Swing high from Oct 2, 20.5% above the price.
52-week high$10.99
From Dec 23, 2025, 259.2% above the price.
52-week low$2.55
From Oct 19, 16.7% below the price.
Chart patternNone
No triangle, channel, or wedge in the last year.
Bollinger Bands (20, 2)Inside
The bands run from $2.54 to $3.39.
Volume0.8x
Against its 20-day average, for the time of day.

The deep dive on LXEO

What it does and how it makes money1 findingFor Pro members1 finding on what LXEO does and how it makes money, for Pro members
Where it stands1 findingFor Pro members1 finding on where LXEO stands: its cash, debt, and share count, for Pro members
What changed in its filings3 findings"On December 7, 2023, we filed a motion to dismiss the complaint, which is now fully briefed and pending before the court." (10-K for fiscal 2022)SEC filing · Mar 11, 2024
Who holds and trades it2 findingsFor Pro members2 findings on who holds and trades LXEO, for Pro members

6 more findings on LXEO, each with its source, for Pro membersGet in free →

How LXEO ranks in Biotech

LXEO is #289 of 291 by Quality Score.

How LXEO ranks in Biotech
1	KNSAKiniksa Pharmaceuticals International	6/14	21
2	TGTXTG Therapeutics	8/14	19
3	AMGNAmgen	5/14	19
	LGNDLigand Pharmaceuticals		Open for its score
	LRMRLarimar Therapeutics		Open for its score
	LXRXLexicon Pharmaceuticals		Open for its score
	LYCALycia Therapeutics		Open for its score
289	LXEOLexeo Therapeutics	0/14	-13

When does LXEO report earnings, and what happens after?

Expected to report Wed Nov 4, before the open (in 2 days). Expected.

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

+8.9%+5.0%+1.9%

Mar 30May 11Aug 12

Reported	When	Gap	Reaction	5 sessions
Aug 12, 2026Before open	Before open	+1.3%	+1.9%	+3.1%
May 11, 2026Before open	Before open	+2.9%	+5.0%	-12.7%
Mar 30, 2026After close	After close	+11.2%	+8.9%	+19.7%

LXEO closed higher after 3 of its last 4 reports.

All 4 reports, and LXEO's Quality Score going into each

Everyone reporting earnings this week

LXEO share count over time

97% more shares than a year earlier.

Weighted shares, quarter to Jun 30, 2026, both from one filing

Shares of LXEO outstanding, as filed
Shares outstanding	As of
82M	Aug 10, 2026
78.5M	May 7, 2026
74.1M	Mar 27, 2026
73M	Nov 3, 2025

Offerings, shelves, and splits of LXEO, from its filings
From its filings	Filed
Registered shares for a later sale (S-3)	Oct 29, 2026
Registered shares for a later sale (S-3)	Nov 5, 2025
Priced a sale of shares	Oct 17, 2025
Registered shares for a later sale (S-3)	Jun 13, 2025

4 more offerings on file, for Pro members.

Insiders trading LXEO

LXEO insider trades

4 insiders sold $323K across 9 filings in the last 6 months. No open-⁠market buys on record. The newest:

SellLouis Edward Tamayo$20KChief Financial Officerat $4.91 on Aug 18, filed Aug 19

SellLouis Edward TamayoChief Financial Officer$20Kat $4.91 on Aug 18, filed Aug 19

All 9 insider filings on LXEO from the last six months, for Pro members.Get in free →

All LXEO insider trades

LXEO's officers and directors

Officers and directors with a Form 4 in the last 12 months.

Richard Nolan TownsendChief Executive Officer · 6 trades
Louis Edward TamayoChief Financial Officer · 2 trades
Jose Manuel OteroChief Operating Officer · 4 trades
Eric AdlerChief Medical Officer · 1 trade
Jenny RobertsonChief Legal Officer · 1 trade
Narinder Pal BhallaChief Medical Officer · 1 trade
Tai Sandi SeeChief Development Officer · 1 trade

See insider trades by person

Which ETFs hold LXEO?

In ETFs: LXEO is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About Lexeo Therapeutics

Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.

59 employeesNew York, NYlexeotx.com

What Lexeo Therapeutics says it competes with

“The biotechnology and pharmaceutical industries are characterized by rapidly changing technologies, significant competition and a strong emphasis on intellectual property.”

From its annual report, SEC filing · Mar 11, 2024

2 more sentences and what it says it does, for Pro membersGet in free →

LXEO's score card

Lexeo Therapeutics (LXEO): Quality Score -13, Poor, #289 of 291 in Biotech, with its price, on Breakaway — The picture a link to this page shows when it is shared.

Pro members see every line of every stock's score.

What would turn LXEO's score around: 8 things
11 more filings explained, a plain line each
6 more things pulling LXEO's score down

BreakawayAug 19Louis Edward Tamayo sold LXEO$20K at $4.91, filed Aug 19

Alerts are optional.

See LXEO's 14 chart checks

See it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

Straight Answers

As of Nov 2, 2026: LXEO's Quality Score is -13 (Poor), #289 of 291 in Biotech. Insiders sold $323K in the last 6 months (Form 4).

Is LXEO a good stock to buy? What its Quality Score says

LXEO scores -13 today, which Breakaway calls Poor. It is #289 of 291 in Biotech by Quality Score, with 0 of 14 chart checks firing. Down 25% in 3 months while the S&P 500 was flat. Cash lasts about 10 quarters at its spending (to Jun 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is LXEO's Quality Score?

LXEO scores -13 today, which Breakaway calls Poor (below zero). That is #289 of 291 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind LXEO's -13.

Are insiders buying LXEO?

4 insiders sold $323K across 9 filings in the last 6 months. No open-⁠market buys on record. The newest is Louis Edward Tamayo, Chief Financial Officer, who sold $20K on Aug 18. Every filing, with the scored weight, for Pro members.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.